Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
- Previous Close
4.4000 - Open
4.4000 - Bid 4.4000 x --
- Ask 4.4100 x --
- Day's Range
4.3700 - 4.4200 - 52 Week Range
3.9100 - 5.5400 - Volume
23,566,483 - Avg. Volume
25,476,335 - Market Cap (intraday)
11.372B - Beta (5Y Monthly) --
- PE Ratio (TTM)
19.13 - EPS (TTM)
0.2300 - Earnings Date --
- Forward Dividend & Yield 0.20 (4.55%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
--
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, manufacturing, and sales of medicines and general health products in China. It offers Chinese herbal decoction pieces, Chinese patent medicines, chemical pharmaceutical products, chemical raw materials, medical devices, and biological products. The company also provides pharmaceutical dosage forms, including tablets, capsules, pills, dripping pills, granules, powders, injections, freeze-dried powder injections, oral liquids, syrups, nasal drops, ointments, etc. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1993 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.
www.conbagroup.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600572.SS
View MorePerformance Overview: 600572.SS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600572.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600572.SS
View MoreValuation Measures
Market Cap
11.37B
Enterprise Value
10.88B
Trailing P/E
19.13
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.78
Price/Book (mrq)
1.62
Enterprise Value/Revenue
1.71
Enterprise Value/EBITDA
14.49
Financial Highlights
Profitability and Income Statement
Profit Margin
9.34%
Return on Assets (ttm)
3.86%
Return on Equity (ttm)
8.52%
Revenue (ttm)
6.38B
Net Income Avi to Common (ttm)
595.75M
Diluted EPS (ttm)
0.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
770.53M
Total Debt/Equity (mrq)
3.88%
Levered Free Cash Flow (ttm)
145.28M